Lab
Cellvio Biomedical LLC
Cellvio Biomedical LLC was paid $502K by Medicaid between Mar 2022 and Jun 2022, across 4 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 70% of everything it billed.
33Billing provider infoCELLVIO BIOMEDICAL LLC
RARITAN, NJ 08869
RARITAN, NJ 08869
33aNPI1114690534assigned 07/30/2021
33bProvider typeClinical Medical Laboratory
28Total paid$502K
24GClaims19,092
24DCodes billed4
24AFirst – last monthMar 2022 – Jun 2022
Compared with peers
Next to other Clinical Medical Laboratory providers in New Jersey
Rank by total paid#73 of 122
Median peer was paid$1.29M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 19,092 | $502K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 70% | 6,459 | 4,090 | $351K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 22% | 6,097 | 3,902 | $108K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 8.5% | 6,514 | 4,091 | $43K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 22 | 21 | $903.89 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPAYVANDI, FARIBOURZ (CEO)